Trial · NCT03192735
Apatinib Combined With SOX Neoadjuvant Therapy for Locally Advanced Gastric Cancer
NCT03192735, Phase 2, Unknown, Chang-Ming Huang, Prof.
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Apatinib Combined With SOX Neoadjuvant Therapy for Locally Advanced Gastric Cancer. Trials, record NCT03192735. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03192735
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Apatinib Combined With SOX Neoadjuvant Therapy for Locally Advanced Gastric Cancer
- NCT number
- NCT03192735
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 50 participants, estimated
- Lead sponsor
- Chang-Ming Huang, Prof.
- Conditions
- Apatinib Combined, SOX, Neoadjuvant Therapy, Locally Advanced Gastric Cancer
- Interventions
- ApatinibMesylateTablets
- First posted
- 2017-06-20
- Last updated
- 2020-02-05
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Radical surgical resection rate | 30 days | Radical surgical resection rate is defined as the rate of R0 resection |
| Secondary | Pathological response rate | 30 days | Briefly, pathCR (Pathological complete rate) was defined as an absence of carcinoma cells in the primary site, and pathologic partial response (pathPR) was defined as less than 10% residual carcinoma cells in the specimen. |
| Secondary | overall response rate | 30 days | according to Response Evaluation Criteria in Solid Tumors RECIST Version 1.1 |
| Secondary | 5-year overall survival rate | 60 months | |
| Secondary | 5-year disease free survival rate | 60months | |
| Secondary | overall postoperative morbidity rates | 30 days | Refers to the incidence of early postoperative complications. The early postoperative complication are defined as the event observed within 30 days after surgery. |
| Secondary | Duration of postoperative hospital stay | 30 days | Duration of postoperative hospital stay in days is used to assess the postoperative recovery course. |
| Secondary | 30 days mortality rates | 30 days | Defined as the event observed within 30 days after surgery. |
| Secondary | adverse event | 60 months | An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event (AE) can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 34241629 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03192735
GET https://conductscience.org/api/trials/v1/NCT03192735/registered